Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lipopolysaccharide + BCTC
- Development stage
- Unknown
- Lead developer
- Stefan Heber
- Modality
- Small Molecules
- Administration
- Intradermal
01
Overview
A research drug combination consisting of the bacterial endotoxin lipopolysaccharide (LPS) and the small molecule TRPV1 antagonist BCTC. This combination is utilized in clinical research models, notably by Stefan Heber at the Medical University of Vienna, to investigate the molecular pathways of inflammatory pain and hyperalgesia in human skin. LPS is administered intradermally to induce a localized inflammatory response and pain sensitization via Toll-like receptor 4 (TLR4) activation, while BCTC is co-administered or subsequently administered to evaluate the specific contribution of the Transient receptor potential vanilloid 1 (TRPV1) ion channel to acid-induced pain within the inflamed tissue. This experimental setup allows researchers to differentiate between various mechanisms of pain hypersensitivity in a controlled human model.
- Other names
- lipopolysaccharide + N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carbox-amideLPS + BCTClipopolysaccharide + BCTC-Stefan Heber-inflammatory pain
02
Targets
TRPV1 (Transient receptor potential cation channel subfamily V member 1)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on lipopolysaccharide + BCTC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lipopolysaccharide + BCTC.